Pharmaceutical

CHMP backs MSD’s KEYTRUDA approval for urothelial carcinoma

The EMA CHMP has recommended approving MSD’s KEYTRUDA regimen as a first-line treatment for urothelial carcinoma.

Jul 30, 2024 - 04:00
CHMP backs MSD’s KEYTRUDA approval for urothelial carcinoma
The EMA CHMP has recommended approving MSD’s KEYTRUDA regimen as a first-line treatment for urothelial carcinoma.
Read the original article

Tags:

Previous Article

Bristol Myers Squibb reports dip in net income for Q2 2024

Next Article

New AI model boosts early osteoporosis diagnosis for ageing populations

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Mitch McConnell’s abrupt episode has an important public health takeaway

Mitch McConnell’s abrupt episode has an important publi...

Jul 28, 2023

STAT+: Neuralink can now study its brain implant in humans, but it’s still catching up to its peers

STAT+: Neuralink can now study its brain implant in hum...

May 27, 2023

Opinion: Medicine robs physicians of their fertility. Here’s how to fix it

Opinion: Medicine robs physicians of their fertility. H...

Aug 19, 2023